ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | February 2012 |
| End Date: | December 2014 |
The investigators propose a proof-of-concept, pathogenesis-oriented, randomized,
placebo-controlled pilot study to assess whether the addition of an angiotensin converting
enzyme (ACE) inhibitor to standard Highly Active Antiretroviral Therapy (HAART) reverses
lymphoid fibrosis, and whether this leads to more effective HIV-specific host immune
responses and an accelerated clearance of the latent reservoir.
placebo-controlled pilot study to assess whether the addition of an angiotensin converting
enzyme (ACE) inhibitor to standard Highly Active Antiretroviral Therapy (HAART) reverses
lymphoid fibrosis, and whether this leads to more effective HIV-specific host immune
responses and an accelerated clearance of the latent reservoir.
Inclusion Criteria include:
- Stable HAART with maintenance of plasma HIV RNA levels below level of detection (<
40-75 copies/mL) for ≥ 12 months
- > 90% adherence to HAART within preceding 30 days
Exclusion Criteria include:
- Screening systolic blood pressure < 110mm Hg or diastolic blood pressure < 60mm Hg
- Current use of any ACE inhibitor, angiotensin receptor blocker, or aldosterone
antagonist
- Known diabetes mellitus or cardiovascular/kidney/collagen vascular disease
- Pregnant/breastfeeding women.
We found this trial at
1
site
San Francisco General Hospital San Francisco General Hospital and Trauma Center (SFGH) is an essential...
Click here to add this to my saved trials
